Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Palvella Therapeutics ( (PVLA) ) has issued an update.
On May 15, 2025, Palvella Therapeutics reported its first-quarter financial results and provided a corporate update. The company announced that its Phase 3 SELVA trial for QTORIN rapamycin exceeded its enrollment target, with results expected in early 2026, and its Phase 2 TOIVA trial is on track for results in late 2025. Palvella’s cash reserves are projected to fund operations into the second half of 2027, indicating strong financial health. The company also highlighted the potential market opportunity for QTORIN rapamycin as the first targeted therapy for rare genetic skin diseases, which could significantly impact its market positioning.
The most recent analyst rating on (PVLA) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.
Spark’s Take on PVLA Stock
According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.
Palvella Therapeutics’ overall score reflects significant financial challenges, particularly in revenue and profitability, which are partially offset by a robust cash position and no debt. Positive corporate developments, such as clinical advancements and strategic financing, provide potential growth opportunities. However, valuation concerns due to negative earnings and the absence of dividends weigh on the score.
To see Spark’s full report on PVLA stock, click here.
More about Palvella Therapeutics
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare genetic skin diseases that currently have no FDA-approved treatments. The company’s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is being evaluated in clinical trials for microcystic lymphatic malformations and cutaneous venous malformations.
Average Trading Volume: 79,137
Technical Sentiment Signal: Hold
Current Market Cap: $255.3M
See more data about PVLA stock on TipRanks’ Stock Analysis page.